Serum levels of total homocysteine, homocysteine metabolites and of advanced glycation end-products (AGEs) in patients after renal transplantation

Clinical Nephrology

Volumn 59, Issue 2, 2003, Pages 88-97

  Franke, S ^a   Muller A ^a   Sommer, M ^a   Busch, M ^a   Kientsch Engel, R ^b   Stein, G ^a  

^a FRIEDRICH SCHILLER UNIVERSITY JENA   (Germany)

^b ROCHE DIAGNOSTICS GMBH   (Germany)

Author keywords

Advanced glycation end products; Cardiovascular complications; Homocysteine; Renal transplantation; Risk factor

Indexed keywords

6 N CARBOXYMETHYLLYSINE; ADVANCED GLYCATION END PRODUCT; ANGIOTENSIN 1 RECEPTOR ANTAGONIST; ANTIHYPERTENSIVE AGENT; AZATHIOPRINE; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; CYCLOSPORIN A; CYSTATHIONINE; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; HOMOCYSTEINE; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; IMMUNOSUPPRESSIVE AGENT; METHYLMALONIC ACID; PENTOSIDINE; STEROID; TACROLIMUS; VITAMIN;

ACUTE GRAFT REJECTION; ADULT; AMINO ACID BLOOD LEVEL; ARTICLE; BLOOD ANALYSIS; CARDIOVASCULAR DISEASE; CARDIOVASCULAR RISK; CONTROLLED STUDY; CORRELATION ANALYSIS; ENZYME LINKED IMMUNOSORBENT ASSAY; FEMALE; GAS CHROMATOGRAPHY; HEART LEFT VENTRICLE HYPERTROPHY; HEMATOLOGICAL PARAMETERS; HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; HUMAN; HYPERHOMOCYSTEINEMIA; HYPERTENSION; KIDNEY DYSFUNCTION; KIDNEY GRAFT REJECTION; KIDNEY TRANSPLANTATION; LOGISTIC REGRESSION ANALYSIS; MAJOR CLINICAL STUDY; MALE; MASS SPECTROMETRY; METABOLITE; RECIPIENT;

EID: 0037321605     PISSN: 03010430     EISSN: None     Source Type: Journal    
DOI: 10.5414/CNP59088     Document Type: Article

References (30)

1. Blacher J, Demuth K, Guerin AP et al 1999 Association between plasma homocysteine concentrations and cardiac hypertrophy in end-stage renal disease. J Nephrol 22: 248-255
2. Bostom A 2000 Homocysteine: "expensive creatinine" or important, modifiable risk factor for arteriosclerotic outcomes in renal transplant recipients? J Am Soc Nephrol 11: 149-151
3. Bostom AG, Gohh RY, Beaulieu AJ et al 1997 Treatment of hyperhomocysteinemia in renal transplant recipients - a randomized, placebo-controlled trial. Ann Int Med 127: 1089-1092
4. Bostom AG, Shemin D, Verhoef P, Nadeau MR, Jaques PF, Selhub J, Dworkin L, Rosenberg IH 1997 Elevated fasting plasma homocysteine levels and cardiovascular disease outcomes in maintenance dialysis patients. Arterioscler Thromb Vasc Biol 17: 2554-2558
5. Boushey CJ, Beresford SAA, Omenn GS, Motulsky AG 1995 A quantitative assessment of plasma homocysteine as a risk factor for vascular disease: probable benefits of increasing folic acid intakes. JAMA 274: 1049-1057
6. Clarke R, Daly L, Robinson K, Naughten E, Cahalane S, Fowler B, Graham I 1991 Hyperhomocysteinemia: an independent risk factor for vascular disease. N Engl J Med 324: 1149-1155
7. Danesh J, Lewington S 1998 Plasma homocysteine and coronary heart disease: systematic review of published epidemiological studies. J Cardiovasc Risk 5: 229-232
8. Ducloux D, Motte G, Challier B, Gibey R, Chalopin JM 2000 Serum total homocysteine and cardiovascular disease occurence in chronic, stable renal transplant recipients: a prospective study. J Am Soc Nephrol 11: 134-137
9. Ducloux D, Ruedin C, Gibey R et al 1998 Prevalence, determinants and clinical significance of hyperhomocyst(e)inaemia in renal-transplant recipients. Nephrol Dial Transplant 13: 2890-2893
10. Elli A, Traversi L, Ponticelli C 2000 Cardiovascular risk factors in renal transplant recipients. Int J Artif Organs 23: 730-735
11. Fernandez-Miranda C, Gomez P, Diaz-Rubio P et al 2000 Plasma homocysteine levels in renal transplanted patients on cyclosporine or tacrolimus therapy: effect of treatment with folic acid. Clin Transplant 14: 110-114
12. Friedlander MA, Hricik DE 1997 Optimizing end-stage renal disease therapy for patients with diabetes mellitus. Semin Nephrol 17: 331-345
13. Graham IM, Leslie ED, Refsum MH et al 1997 Plasma homocysteine as a risk factor for vascular disease: The European Concerted Action Project. JAMA 277: 1775-1781
14. Henning BF, Riezler R, Tepel M et al 1999 Evidence of altered homocysteine metabolism in chronic renal failure. Nephron 83: 314-322
15. Hofmann MA, Kohl B, Zumbach MS et al 1998 Hyperhomocyst(e)inemia and endothelial dysfunction in IDDM. Diabetes Care 21: 841-848
16. Hricik DE, Wu YE, Schulak JA, Friedlander MA 1996 Disparate changes in plasma and tissue pentosidine levels after kidney and kidney-pancreas transplantation. Clin Transplant 10: 568-573
17. Miyata T, Ueda Y, Shinzato T et al 1996 Accumulation of albumin-linked and free-form pentosidine in the circulation of uremic patients with end-stage renal failure: Renal implications in the pathophysiology of pentosidine. J Am Soc Nephrol 7: 1198-1206
18. Miyata T, Ueda Y, Yoshida A et al 1997 Clearance of pentosidine, an advanced glycation end product, by different modalities of renal replacement therapy. Kidney Int 51: 880-887
19. Miyata T, Ishikawa S, Asahi K et al 1999 2-Isopropylidenehydrazono-4-oxo-thiazolidin-5-ylacetanilide (OPB-9195) treatment inhibits the development of intimal thickening after balloon injury of rat carotid artery: role of glycoxidation and lipoxidation reactions in vascular tissue damage. FEBS Lett 445: 202-206
20. Miyata T, van Ypersele de Strihou C, Kurokawa K, Baynes JW 1999 Alterations in nonenzymatic biochemistry in uremia: origin and significance of "carbonyl stress" in long-term uremic complications. Kidney Int 55: 389-399
21. Moustapha A, Naso A, Nahlawi M et al 1998 Prospective study of hyperhomocysteinemia as an adverse cardiovascular risk factor in end-stage renal disease. Circulation 97: 138-141
22. Niwa T, Katsuzaki T, Miyazaki S et al 1997 Immunohistochemical detection of imidazolone, a novel advanced glycation end product, in kidneys and aortas of diabetic patients. J Clin Invest 99: 1272-1280
23. Parfrey PS, Foley RN 1999 The clinical epidemiology of cardiac disease in chronic renal failure. J Am Soc Nephrol 10: 1606-1615
24. Parfrey PS 1999 Pathogenesis of cardiac disease in dialysis patients. Semin Dial 12: 62-68
25. Stabler SP, Estacio R, Jeffers BW, Cohen JA, Allen RH, Schrier RW 1999 Total homocysteine is associated with nephropathy in non-insulin-dependent diabetes mellitus. Metabolism 48: 1096-1101
26. Starkebaum G, Harlan JM 1986 Endothelial cell injury due to copper-catalyzed hydrogen peroxide generation from homocysteine. J Clin Invest 77: 1370-1376
27. Sugiyama S, Miyata T, Ueda Y et al 1998 Plasma levels of pentosidine in diabetic patients: an advanced glycation end product. J Am Soc Nephrol 9: 1681-1688
28. Wells-Knecht KJ, Brinkmann E, Wells-Knecht MC et al 1996 New biomarkers of Maillard reaction damage to proteins. Nephrol Dial Transplant 11 (Suppl 5): 41-47
29. Wheeler DC, Steiger J 2000 Evolution and etiology of cardiovascular diseases in renal transplant recipients. Transplantation 70: SS41-SS45
30. Yoshida S, Yamada K, Hamaguchi K et al 1998 Immunohistochemical study of human advanced glycation end-products (AGE) and growth factors in cardiac tissues of patients on maintenance dialysis and with kidney transplantation. Clin Nephrol 49: 273-280